Sena K. Biswas

VIMAC Ventures LLC (VIMAC Ventures) is a venture capital firm founded in 1982. The firm is headquartered in Boston, Massachusetts.

Angiochem, Inc. is a clinical-stage biotechnology company, which engages in the development of pharmaceutical drugs for brain diseases and brain-related disorders. It offers small molecules and biologics, for the treatment of central nervous system diseases including primary brain cancer, brain metastases, lysosomal storage diseases, and pain. The company founded by Richard Béliveau in 2003 and is headquartered in Montreal, Canada.

TL Ventures Inc (TL Ventures) is a venture capital subsidiary of Safeguard Scientifics, Inc. founded in 1988 by Robert Keith. The firm is headquartered in Wayne, Pennsylvania.

Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ.

Bear, Stearns & Co., Inc. is a global investment banking, securities trading and brokerage firm located in New York City with additional offices in Dallas, Boston and San Francisco. The firm is a subsidiary Bear Sterns Cos., Inc. (NYSE: BSC). Their equity research team consists of senior analysts located throughout the world. In addition to domestic coverage, they have research teams focusing on Latin America, Asia and Europe. The analysts use a bottom-up approach to stock selection. The Bear Stearns fixed-income research department provides coverage of every sector of the fixed-income universe. The financial analytics and structured transactions group (F.A.S.T) provides investment research, fixed-income portfolio management and analytical systems, trading technology and general financial expertise. The group also provides a broad range of services to financial institutions including asset-liability management, balance sheet restructuring, receivables-based financing analysis, security and portfolio analysis, peer analysis, and historical and real-time market-based information.

Combinent BioMedical Systems, Inc. developed novel drug combinations and formulations. The company was founded by William F. Crowley, Jr. and Robert S. Langer, Jr. in 2000 and was headquartered in Lexington, MA.

Neotropix, Inc. develops virus-based therapies for cancer treatment. It has developed NTX-010 virus, a small cell lung cancer treatment and as a treatment of pediatric cancers, such as neuroblastoma. The company was founded by Paul L. Hallenbeck in 2003 and is headquartered in Malvern, PA.

Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.

Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada.